We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Bladder Cancer

Journal Scan / Research · July 26, 2022

ARID1A-Deficient Bladder Cancer Is Dependent on PI3K Signaling and Sensitive to EZH2 and PI3K Inhibitors

JCI insight


Additional Info

Disclosure statements are available on the authors' profiles:

JCI insight
ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors
JCI Insight 2022 Jul 19;[EPub Ahead of Print], H Rehman, DS Chandrashekar, C Balabhadrapatruni, S Nepal, SAH Balasubramanya, AK Shelton, KR Skinner, AH Ma, T Rao, ML Eich, AD Robinson, G Naik, U Manne, GJ Netto, CR Miller, CX Pan, G Sonpavde, S Varambally, JE Ferguson

Further Reading